Home

Antiviral therapy for chronic HBV during pregnancy

Written by Bogomolov P.O., Matsievich M.V., Voronkova N.V., Kuzmina O.S.

  UDK: 616.36–002.2–055.6–085.281 | Pages: 22–26 | Full text PDF | Open PDF 

Annotation:

Chronic hepatitis B treatment during pregnancy is an extremely difficult task. Regardless immunoprophylaxis a significant proportion of children, born of mothers with high viraemia, is infect-ed with hepatitis B virus. Accumulating data suggests that antiviral therapy is an effective therapy procedure in III trimester for immunoprophylaxis failed. To minimize the counterparts of nucleosi(ti)des impact on embryo antiviral therapy during pregnancy should be prescribed to women at high risk of progressive disease and/ or hepatic decompensation. Currently received safety data gives evidence of telbivudin and tenofovir may be taken during pregnancy. At the same time antiviral therapy requires a careful assessment of risk-benefit ratio.

Links to authors:

P.O. Bogomolov1, M.V. Matsievich1, N.V. Voronkova1, O.S. Kuzmina2
1 Moscow’s regional research clinical institute n.a. M.F. Vladimirskiy (61/2 Schepkin str., Moscow, 129110),
2 Podolsk clinical hospital (38, Kirova str., Podolsk, 142100)


1. Alimenti A., Burdge D.R., Ogilvie G.S. [et al.] Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy // Pediatr. Infect. Dis. J. 2003. Vol. 22, No. 9. P. 782–789.
2. Antiviral Pregnancy Registry (APR). Antiviral Pregnancy Registry Interim Report 1, January 1989 through 31 January 2012. URL: http://APregistry.com2012 (date of acccess: 01.11.2012).
3. Beasley R.P., Stevens C.E., Shiao I.S., Meng H.C. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B // Lancet. 1975. Vol. 2 (7938). P. 740–741.
4. Burk R.D., Hwang L.Y., Ho G.Y. [et al.] Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load // J. Infect. Dis. 1994. Vol. 170, No. 6. P. 1418–1423.
5. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection // J. Hepatol. 2012. Vol. 57, No. 1. P. 167–185.
6. Gambarin-Gelwan M. Hepatitis B in pregnancy // Clin. Liver Dis. 2007. Vol. 11, No. 4. P. 945–963.
7. Gibb D.M., Kizito H., Russell E.C. [et al.] DART trial team. Pregnancy and infant outcomes among HIV-infected women taking long-term ARTwithandwithout tenofovir in the DART trial // PLoSMed. 2012. Vol. 9, No. 5. P. e1001217.
8. Han G.R., Cao M.K., Zhao W. [et al.] A prospective and openlabel study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection // J. Hepatol. 2011. Vol. 55, No. 6. P. 1215–1221.
9. Han G.R., Jiang X.H., Zhao W. [et al.] Lamivudine use in the 2nd or 3rd trimester of pregnancy has similar efficacy in preventing vertical transmission of chronic hepatitis B in highly viremic mothers // Hepatology. 2011. Vol. 54 (S4). P. 479A.
10. Hill J.B., Sheffield J.S., Kim M.J. [et al.] Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers // Obstet. Gynecol. 2002. Vol. 99, No. 6. P. 1049–1052.
11. Lin H.H., Wu W.Y., Kao J.H., Chen D.S. Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: correlation with viral characteristics // J. Gastroenterol. Hepatol. 2006. Vol. 21, No. 3. P. 605–609.
12. Lok A.S.F., McMahon B.J. Chronic hepatitis B: update 2009 // Hepatology. 2009. Vol. 50, No. 3. P. 661–662.
13. Pan C., Zhang H., Pang Q. [et al.] Real world data on the efficacy and safety of telbivudine or lamivudine use in late pregnancy for the prevention of perinatal transmission of hepatitis B virus to the infants // Hepatology. 2012. Vol. 56 (S1). P. 368A.
14. Pan C.Q., Duan Z.P., Bhamidimarri K.R. [et al.] An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus // Clin. Gastroenterol. Hepatol. 2012. Vol. 10, No. 5. P. 452–459.
15. Pan C.Q., Han G.R., Jiang H.X. [et al.] Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B // Clin. Gastroenterol. Hepatol. 2012. Vol. 10, No. 5. P. 520–526.
16. Pan C.Q., Mi L.J., Bunchorntavakul C. [et al.] Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series // Dig. Dis. Sci. 2012. Vol. 57, No. 9. P. 2423–2429.
17. Shah I. Lactic acidosis in HIV-exposed infants with perinatal exposure to antiretroviral therapy // Ann. Trop. Paediatr. 2009. Vol. 29, No. 4. P. 257–261.
18. Shaheen A.A., Myers R.P. The outcomes of pregnancy in patients with cirrhosis: a population-based study // Liver Int. 2010. Vol. 30, No. 2. P. 275–283.
19. Söderström A., Norkrans G., Lindh M. Hepatitis B virus DNA during pregnancy and postpartum: aspects on vertical transmission // Scand. J. Infect. Dis. 2003. Vol. 35, No. 11–12. P. 814–819.
20. Tan H.H., Lui H.F., Chow W.C. Chronic hepatitis B virus (HBV) infection in pregnancy. // Hepatol. Int. 2008. Vol. 2, No. 3. P. 370–375.
21. Ter Borg M.J., Leemans W.F., de Man R.A., Janssen H.L. Exacerbation of chronic hepatitis B infection after delivery // J. Viral. Hepat. 2008. Vol. 15, No. 1. P. 37–41.
22. Van Rompay K.K., Hamilton M., Kearney B., Bischofberger N. Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques // Antimicrob. Agents Chemother. 2005. Vol. 49, No. 5. P. 2093–2094.
23. Weinbaum C.M., Williams I., Mast E.E. [et al.] Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection // MMWR Recomm. Rep. 2008. Vol. 57 (RR-8). P. 1–20.
24. Wiseman E., Fraser M.A., Holden S. [et al.] Perinatal transmission of hepatitis B virus: an Australian experience // Med. J. Aust. 2009. Vol. 190, No. 9. P. 489–492.
25. World Health Organization. Hepatitis B Fact sheet, July 2012. URL: http://www.who.int/mediacentre/factsheets/fs204/ en (дата обращения: 01.11.2012).
26. Xu D.Z., Yan Y.P., Choi B.C. [et al.] Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study // J. Med. Virol. 2002. Vol. 67, No. 1. P. 20–26.
27. Xu W.M., Cui Y.T., Wang L. [et al.] Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study // J. Viral. Hepat. 2009. Vol. 16, No. 2. P. 94–103.
28. Yang Y.B., Li X.M., Shi Z.J., Ma L. Pregnant woman with fulminant hepatic failure caused by hepatitis B virus infection: a case report // World J. Gastroenterol. 2004. Vol. 10, No. 15. P. 2305–2306.
29. Zou H., Chen Y., Duan Z. [et al.] Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers // J. Viral. Hepat. 2012. Vol. 19, No. 2. P. e18–e25.

PUBLISHER: "MEDITSYNA DV"

Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.